RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis

• Published in: Respiratory research 2006-06, Vol.7 (1), p.88-88, Article 88
• Main Authors: Watts, K L, Cottrell, E, Hoban, P R, Spiteri, M A
• Format: Article
• Language: English
• Subjects: ADP Ribose Transferases - pharmacology; Bone morphogenetic proteins; Botulinum Toxins - pharmacology; Cell Division - drug effects; Cell Division - physiology; Cell Line; Comparative analysis; Connective Tissue Growth Factor; Cyclin D1 - genetics; Cyclin D1 - metabolism; Enzyme-linked immunosorbent assay; Fibroblasts - metabolism; Fibroblasts - pathology; G1 Phase - drug effects; G1 Phase - physiology; Gene Expression - physiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Immediate-Early Proteins - pharmacology; Intercellular Signaling Peptides and Proteins - pharmacology; Lung - cytology; Pulmonary fibrosis; Pulmonary Fibrosis - metabolism; Pulmonary Fibrosis - pathology; Respiratory tract diseases; rhoA GTP-Binding Protein - antagonists & inhibitors; rhoA GTP-Binding Protein - metabolism; RNA; Signal Transduction - drug effects; Signal Transduction - physiology; Simvastatin; Simvastatin - pharmacology; Transforming Growth Factor beta - pharmacology; Transforming Growth Factor beta1; Transforming growth factors; Up-Regulation - drug effects; Up-Regulation - physiology
• ISSN: 1465-993X; 1465-9921; 1465-993X
• DOI: 10.1186/1465-9921-7-88

Idiopathic Pulmonary Fibrosis (IPF) is a debilitating disease characterized by exaggerated extracellular matrix deposition and aggressive lung structural remodeling. Disease pathogenesis is driven by fibroblastic foci formation, consequent on growth factor overexpression and myofibroblast proliferation. We have previously shown that both CTGF overexpression and myofibroblast formation in IPF cell lines are dependent on RhoA signaling. As RhoA-mediated regulation is also involved in cell cycle progression, we hypothesise that this pathway is key to lung fibroblast turnover through modulation of cyclin D1 kinetic expression. Cyclin D1 expression was compared in primary IPF patient-derived fibroblasts and equivalent normal control cells. Quantitative real time PCR was employed to examine relative expression levels of cyclin D1 mRNA; protein expression was confirmed by western blotting. Effects of Rho signaling were investigated using transient transfection of constitutively active and dominant negative RhoA constructs as well as pharmacological inhibitors. Cellular proliferation of lung fibroblasts was determined by BrdU incorporation ELISA. To further explore RhoA regulation of cyclin D1 in lung fibroblasts and associated cell cycle progression, an established Rho inhibitor, Simvastatin, was incorporated in our studies. Cyclin D1 expression was upregulated in IPF compared to normal lung fibroblasts under exponential growth conditions (p < 0.05). Serum deprivation inhibited cyclin D1 expression, which was restored following treatment with fibrogenic growth factors (TGF-beta1 and CTGF). RhoA inhibition, using a dominant negative mutant and a pharmacological inhibitor (C3 exotoxin), suppressed levels of cyclin D1 mRNA and protein in IPF fibroblasts, with significant abrogation of cell turnover (p < 0.05). Furthermore, Simvastatin dose-dependently inhibited fibroblast cyclin D1 gene and protein expression, inducing G1 cell cycle arrest. Similar trends were observed in control experiments using normal lung fibroblasts, though exhibited responses were lower in magnitude. These findings report for the first time that cyclin D1 expression is deregulated in IPF through a RhoA dependent mechanism that influences lung fibroblast proliferation. This potentially unravels new molecular targets for future anti-IPF strategies; accordingly, Simvastatin inhibition of Rho-mediated cyclin D1 expression in IPF fibroblasts merits further exploitation.